First human test of new drug ARGX-109 completed
NCT ID NCT06799416
Summary
This was an early-stage study to check the safety of a new drug called ARGX-109 in healthy adults. Researchers gave a single injection to 40 volunteers and monitored them for about 20 weeks to see how their bodies reacted to the drug and how it moved through their system. The main goal was to find a safe dose and understand the drug's basic effects before testing it in people with a specific disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Altasciences - Montreal - Phase I unit
Mount Royal, Quebec, H3P 3P1, Canada
Conditions
Explore the condition pages connected to this study.